Bayer receives approval for Gadovist injection in Japan

March 26, 2015
1 min read

The FINANCIAL — Bayer HealthCare received approval in Japan for Gadovist (gadobutrol) injection for use with magnetic resonance imaging (MRI). Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan and is indicated for contrast-enhancement MRI in cranial, spinal, the body and extremeties at a dose of 0.1 mL/kg body weight.

In Japan, there are more than 1.6 million MRI procedures conducted annually which are contrast-enhanced, according to Bayer.

“The approval of Gadovist in Japan provides local radiologists with access to the first high concentration/high relaxivity gadolinium-based contrast agent,” said Dr. Christiane Pering, Chief Medical Officer (CMO) and Head of Innovation within Bayer HealthCare’s Medical Care division. “Gadovist has demonstrated efficacy in providing the potential of high quality images of the central nervous system and whole body for patients supporting effective diagnosis and disease management by their healthcare teams and ultimately enabling good patient care.”

The approval of Gadovist in Japan was based on two key clinical studies involving patients from Japan. A 223-patient Phase 3 open label study in Japan demonstrated superiority of gadobutrol-enhanced MRI of the central nervous system (CNS) compared to unenhanced MRI. A 363-patient Pan-Asian Phase 3 study with 120 Japanese patients demonstrated non-inferiority of gadobutrol-enhanced MR images of the body (breast, heart, abdomen, kidney, pelvis and extremity) to those obtained through the use of gadopentetate dimeglumine. These studies and other supportive studies provided safety data on more than 550 Japanese patients dosed with Gadovist. Studies submitted to the health authority in Japan totaled 6599 patients, of which more than 1900 were Asian, and demonstrated that the safety profile of gadobutrol in the Asian population was consistent with global clinical studies.

Gadovist is formulated at twice the concentration (1 M/L) of other gadolinium-based contrast agents (GBCAs), resulting in a lower volume per administration and a more compact contrast bolus. It also has greater relaxivity than other GBCAs. Relaxivity is a measure of the ability of MR-contrast agents, to shorten the relaxation times. A high-relaxivity contrast agent may improve signal intensity and contrast enhancement in MR images.

 

Leave a Reply

Related stories


Fatal error: Uncaught Error: Call to a member function have_posts() on null in /home/slonfcxh/public_html/wp-content/themes/fox/data/archive.php:731 Stack trace: #0 /home/slonfcxh/public_html/wp-content/themes/fox/widgets/latest-posts/widget.php(273): fox56_blog_list() #1 /home/slonfcxh/public_html/wp-content/themes/fox/widgets/latest-posts/register.php(33): include('/home/slonfcxh/...') #2 /home/slonfcxh/public_html/wp-includes/class-wp-widget.php(394): Wi_Widget_Latest_Posts->widget() #3 /home/slonfcxh/public_html/wp-includes/widgets.php(847): WP_Widget->display_callback() #4 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(418): dynamic_sidebar() #5 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(136): fox56_single_sidebar() #6 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(7): fox56_single_inner() #7 /home/slonfcxh/public_html/wp-content/themes/fox/single.php(23): fox56_single() #8 /home/slonfcxh/public_html/wp-includes/template-loader.php(132): include('/home/slonfcxh/...') #9 /home/slonfcxh/public_html/wp-blog-header.php(19): require_once('/home/slonfcxh/...') #10 /home/slonfcxh/public_html/index.php(17): require('/home/slonfcxh/...') #11 {main} thrown in /home/slonfcxh/public_html/wp-content/themes/fox/data/archive.php on line 731